(DBD) Diebold Nixdorf - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2536512021

Atm, Cash, Recyclers, Pos, Kiosks

Application Software
Market Cap in USD: 2,469m

IPO / Inception:
12m vs SPY: 43.4%

EPS (Earnings per Share)

EPS CAGR: 130.74%
EPS Trend: 44.9%

Last SUE: 0.29
Qual. Beats: 0

Revenue

Rev. CAGR: -3.00%
Rev. Trend: 12.7%

Last SUE: 0.18
Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	37.2%
Value at Risk 5%th	56.5%
Relative Tail Risk	-7.71%

Reward TTM
Sharpe Ratio	1.58
Alpha	47.18
CAGR/Max DD	2.59

Character TTM
Hurst Exponent	0.412
Beta	1.181
Beta Downside	1.248

Drawdowns 3y
Max DD	25.76%
Mean DD	6.55%
Median DD	5.16%

Description: DBD Diebold Nixdorf December 01, 2025

Diebold Nixdorf (NYSE: DBD) delivers end-to-end automation and digitisation solutions for banking and retail, split into Banking and Retail segments. Its portfolio includes cash recyclers, intelligent deposit terminals, teller-automation tools, kiosk and physical-security hardware, plus software that links front-end consumer touchpoints to back-end transaction processing, analytics, remote asset management and omnichannel commerce.

Beyond hardware, the firm offers a suite of services: proactive remote monitoring, on-site incident resolution, preventive and on-demand maintenance, managed-service outsourcing (including transaction processing and solution upgrades), and cash-management logistics. In retail, DBD supplies the DN Vynamic software platform, modular POS and self-checkout terminals, printers, scales, mobile scanners, and full-cycle store-life-management services.

Key recent metrics: FY 2023 revenue of roughly $1.4 billion, with the Banking segment contributing about 55 % of sales; a 5 % CAGR projected for the global cash-recycling market through 2028; and an operating margin of ~ 7 % despite pressure from declining cash usage as digital payments accelerate. Macro-level drivers include central-bank policies that influence cash demand, the retail shift toward contactless checkout, and the broader trend of banks outsourcing physical-branch infrastructure to improve cost efficiency.

For a deeper, data-driven view of DBD’s valuation and risk profile, you might explore the analyst tools on ValueRay to see how these trends are reflected in the company’s forward-looking metrics.

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income (50.6m TTM) > 0 and > 6% of Revenue (6% = 221.4m TTM)

FCFTA 0.06 (>2.0%) and ΔFCFTA 3.36pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 12.42% (prev 15.45%; Δ -3.03pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.08 (>3.0%) and CFO 279.4m > Net Income 50.6m (YES >=105%, WARN >=100%)

Net Debt (804.8m) to EBITDA (355.4m) ratio: 2.26 <= 3.0 (WARN <= 3.5)

Current Ratio 1.36 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (37.5m) change vs 12m ago -0.27% (target <= -2.0% for YES)

Gross Margin 24.95% (prev 24.04%; Δ 0.91pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 96.80% (prev 97.38%; Δ -0.58pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 2.16 (EBITDA TTM 355.4m / Interest Expense TTM 99.8m) >= 6 (WARN >= 3)

Altman Z'' 1.28

(A) 0.12 = (Total Current Assets 1.72b - Total Current Liabilities 1.26b) / Total Assets 3.72b

(B) 0.01 = Retained Earnings (Balance) 43.9m / Total Assets 3.72b

(D) 0.05 = Book Value of Equity 129.1m / Total Liabilities 2.61b

Total Rating: 1.28 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 62.80

1. Piotroski 6.0pt

2. FCF Yield 7.05%

3. FCF Margin 6.22%

4. Debt/Equity 0.96

5. Debt/Ebitda 2.26

6. ROIC - WACC (= 1.26)%

7. RoE 4.91%

8. Rev. Trend 12.68%

9. EPS Trend 44.91%

What is the price of DBD shares?

As of January 14, 2026, the stock is trading at USD 70.27 with a total of 378,415 shares traded.
Over the past week, the price has changed by +5.26%, over one month by +5.21%, over three months by +23.11% and over the past year by +73.08%.

Is DBD a buy, sell or hold?

Diebold Nixdorf has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy DBD.

Strong Buy: 1
Buy: 0
Hold: 1
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the DBD price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	79	12.4%
Analysts Target Price	79	12.4%
ValueRay Target Price	96.6	37.4%

DBD Fundamental Data Overview January 12, 2026

P/E Trailing = 49.9259
P/E Forward = 12.1655
P/S = 0.6691
P/B = 2.1834
Beta = 1.549
Revenue TTM = 3.69b USD
EBIT TTM = 215.3m USD
EBITDA TTM = 355.4m USD
Long Term Debt = 934.0m USD (from longTermDebt, last quarter)
Short Term Debt = 48.8m USD (from shortTermDebt, last quarter)
Debt = 1.07b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 804.8m USD (from netDebt column, last quarter)
Enterprise Value = 3.26b USD (2.47b + Debt 1.07b - CCE 280.0m)
Interest Coverage Ratio = 2.16 (Ebit TTM 215.3m / Interest Expense TTM 99.8m)
EV/FCF = 14.19x (Enterprise Value 3.26b / FCF TTM 229.5m)
FCF Yield = 7.05% (FCF TTM 229.5m / Enterprise Value 3.26b)
FCF Margin = 6.22% (FCF TTM 229.5m / Revenue TTM 3.69b)
Net Margin = 1.37% (Net Income TTM 50.6m / Revenue TTM 3.69b)
Gross Margin = 24.95% ((Revenue TTM 3.69b - Cost of Revenue TTM 2.77b) / Revenue TTM)
Gross Margin QoQ = 26.23% (prev 25.57%)
Tobins Q-Ratio = 0.87 (Enterprise Value 3.26b / Total Assets 3.72b)
Interest Expense / Debt = 2.04% (Interest Expense 21.8m / Debt 1.07b)
Taxrate = 18.71% (9.60m / 51.3m)
NOPAT = 175.0m (EBIT 215.3m * (1 - 18.71%))
Current Ratio = 1.36 (Total Current Assets 1.72b / Total Current Liabilities 1.26b)
Debt / Equity = 0.96 (Debt 1.07b / totalStockholderEquity, last quarter 1.11b)
Debt / EBITDA = 2.26 (Net Debt 804.8m / EBITDA 355.4m)
Debt / FCF = 3.51 (Net Debt 804.8m / FCF TTM 229.5m)
Total Stockholder Equity = 1.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.33% (Net Income 50.6m / Total Assets 3.72b)
RoE = 4.91% (Net Income TTM 50.6m / Total Stockholder Equity 1.03b)
RoCE = 10.96% (EBIT 215.3m / Capital Employed (Equity 1.03b + L.T.Debt 934.0m))
RoIC = 8.93% (NOPAT 175.0m / Invested Capital 1.96b)
WACC = 7.67% (E(2.47b)/V(3.54b) * Re(10.27%) + D(1.07b)/V(3.54b) * Rd(2.04%) * (1-Tc(0.19)))
Discount Rate = 10.27% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -81.65 | Cagr: -0.13%
[DCF Debug] Terminal Value 73.85% ; FCFF base≈181.4m ; Y1≈131.5m ; Y5≈73.1m
Fair Price DCF = 18.70 (EV 1.48b - Net Debt 804.8m = Equity 670.9m / Shares 35.9m; r=7.67% [WACC]; 5y FCF grow -32.43% → 2.90% )
[DCF Warning] FCF declining rapidly (-32.43%), DCF may be unreliable
EPS Correlation: 44.91 | EPS CAGR: 130.7% | SUE: 0.29 | # QB: 0
Revenue Correlation: 12.68 | Revenue CAGR: -3.00% | SUE: 0.18 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.70 | Chg30d=-0.085 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=5.02 | Chg30d=+0.060 | Revisions Net=+0 | Growth EPS=+21.7% | Growth Revenue=+2.1%

Additional Sources for DBD Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle